Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AdaptHealth Corp. (AHCO) · oqro.io/stocks/AHCO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have AdaptHealth Corp. insiders bought shares recently?
No open-market purchase by an insider of AdaptHealth Corp. was filed in the last 90 days. The latest on record was on Aug 14, 2026.
How often do AdaptHealth Corp. insiders buy and sell shares?
Since 2018, AdaptHealth Corp. insiders reported 47 open-market purchases and 61 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2026.
Who is selling AdaptHealth Corp. stock?
No open-market sale by an insider of AdaptHealth Corp. (AHCO) was filed with the SEC in the last 90 days.
Do members of Congress trade AHCO?
No trade in AdaptHealth Corp. (AHCO) was disclosed by a member of Congress in the last 12 months.
When does AdaptHealth Corp. report its next results?
AdaptHealth Corp.'s next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−20.3% (−$1.85) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $9.10 on Nov 19, 2025 to $7.25 on Nov 19, 2026 (−20.3%). Disclosed in this range: 15 insider trades, 2 pre-arranged insider sales, 0 Congress trades, and 11 13F position changes for 3 quarters ending in it.
2 insiders bought
2 insiders bought
2 insiders bought
$4$6$10$12$14$16$7.25
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 17 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Plymouth Meeting, Pennsylvania.
Last 12 months
−21.0%
S&P 500 +5.7% over the same dates
Market value
$1.06B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 10.9M shares sold short (7.5% of shares outstanding), +6.8% vs the previous count, 5.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2018
Insiders of AdaptHealth Corp. reported 47 open-market purchases and 61 sales since 2018; purchases in 7 different years, most recently 2026.
Year
Bought
Sold
2026
$49.1M14×14 trades
$231K2×2 trades
2025
—
$127K2×2 trades
2024
—
$6M12×12 trades
2023
$10K1×1 trade
$31.9M16×16 trades
2022
$14.1M21×21 trades
$49.4M22×22 trades
2021
$1.82M7×7 trades
$3.25M4×4 trades
2020
$5.3K1×1 trade
$53.7M3×3 trades
2019
$102K1×1 trade
—
2018
—2×2 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Sep 8
Top officer leaving
“Chief Financial Officer Departure The Company announced today that Jason Clemens, the Company’s Chief Financial Officer, will terminate his employment with the Company effective as of October 1, 2026 (the “Separation Date”);”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
When insiders usually buy
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
84%
38 of 45 insider purchases since 2019 came within 30 days after a results announcement
From AdaptHealth Corp.'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know AdaptHealth Corp.'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 3, 2026. Quarterly reports are not audited. Read the filing
By business segment
Sleep Health$394M53%
+11% on the same quarter a year earlier ($355M)
Respiratory Health$191M26%
+7.8% on the same quarter a year earlier ($177M)
Wellness at Home$161M22%
+15% on the same quarter a year earlier ($141M)
Total revenue$746M+11%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
By business segment
Sleep Health$1.38B42%
+2.1% on the year before ($1.35B)
Respiratory Health$691M21%
+6.1% on the year before ($651M)
Diabetes Health$592M18%
−3.6% on the year before ($614M)
Wellness at Home$583M18%
−9.8% on the year before ($646M)
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 15,000 words.
From “AdaptHealth Corp. Overview”, in the company's words
AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment ("HME"), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. A description of the products and services provided within each of the Company’s four reportable segments is provided below.
What the section covers (32 headings)
AdaptHealth Corp. Overview
Sleep Health
Respiratory Health
Diabetes Health
Wellness at Home
Impact of Inflation
Key Components of Operating Results
Factors Affecting AdaptHealth’s Operating Results
Goodwill Impairment
Gain on Sale of Businesses
Seasonality
Key Business Metrics
Consolidated Results of Operations
Comparison of Year Ended December 31, 2025 and Year Ended December 31, 2024
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026 and Form 10-Q filed Nov 3, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 35.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (20.4% on ATS, 14.6% with other brokers), below its 26-week average of 39.7%. Weeks of Sep 21 to Oct 16, 2026.
Total revenue$3.24B−0.5%
And 18 more headings in the filing.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: MS TRAJECTORY CROSS (ATS-1) (20.4%), INTELLIGENT CROSS LLC (10.9%), UBS ATS (8.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 25, 2025. Read the filing
New risk factors in the latest annual report (2 headings)
AdaptHealth’s results of operations may be adversely impacted if expenses under capitated agreements exceed revenues.
If CMS pursued payment reductions to Medicare’s payment rates for CGMs and supplies or takes other actions recommended by the OIG-HHS in its November 2025 report regarding CGMs, AdaptHealth’s revenue, financial condition and results of operations could be negatively impacted.
No longer listed (1 heading from the year before)
We will continue to incur significant expenses and administrative burdens as a result of being a public company, which could have a material adverse effect on AdaptHealth's business, financial condition and results of operations.
Legal proceedings (Item 3)
From time to time and in the normal course of business, the Company is involved in legal proceedings relating to its business. While there can be no assurance, based on the Company’s evaluation of information currently available, the Company’s management, following consultation with legal counsel, does not expect the ultimate disposition of any or a combination of any such legal proceedings to have a material adverse effect on our business, financial condition or operating results.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of AdaptHealth Corp. filed 14 open-market purchases (about $49.1M, in 8 filings, by 5 people) and 3 open-market sales (about $278K, in 3 filings, by 2 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $407K, in 2 filings). (AdaptHealth Corp. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 6 new or larger positions and 5 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. REINHART PARTNERS, LLC. cut its AHCO stake below 5% (0%) (filed Oct 13, 2026).
Contracts, lobbying and filings. FINRA short interest for AHCO on the settlement date of Oct 30, 2026 was 10,928,383 shares (+6.77% on the previous report), about 5.24 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: CSM Advisors, LLC (increased, 168,944 shares); Jupiter Asset Management Ltd (new position); the largest that shrank: Reinhart Partners, Llc. (reduced, 2,666,446 shares); Segall Bryant & Hamill, LLC (reduced, 259,175 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. AdaptHealth Corp. filed a Form 8-K on Sep 8, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors. The company's own opening sentence of that report reads: "Chief Financial Officer Appointment AdaptHealth Corp. (the 'Company') announced today that Harriss Currie, age 64, has been appointed to serve as the Chief Financial Officer of the Company, effective as of September 9, 2026 (the..."
Who holds it. 237 funds reported a stake in AdaptHealth Corp. in their 13F for Q2 2026. The largest by value: OEP CAPITAL ADVISORS, L.P. (11.5% of the value reported), BlackRock, Inc. (11.3% of the value reported), DEERFIELD MANAGEMENT COMPANY, L.P. (8.1% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of AdaptHealth Corp. filed 14 open-market purchases (about $49.1M, in 8 filings, by 5 people) and 3 open-market sales (about $278K, in 3 filings, by 2 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $407K, in 2 filings).
The largest purchase: OEP VII GP, L.L.C., 10% owner, about $7.98M, filed Mar 30, 2026.
The largest sale: Iii Russell E. Schuster, Chief Commercial Officer, about $118K, filed Jul 6, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 6 new or larger positions and 5 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
REINHART PARTNERS, LLC. cut its AHCO stake below 5% (0%) (filed Oct 13, 2026).
Contracts, lobbying and filings
FINRA short interest for AHCO on the settlement date of Oct 30, 2026 was 10,928,383 shares (+6.77% on the previous report), about 5.24 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: CSM Advisors, LLC (increased, 168,944 shares); Jupiter Asset Management Ltd (new position); the largest that shrank: Reinhart Partners, Llc. (reduced, 2,666,446 shares); Segall Bryant & Hamill, LLC (reduced, 259,175 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $10.3M for its principal executive officer, and an average of $3.42M for the other named executive officers.
Company reports, price and press
AdaptHealth Corp. filed a Form 8-K on Sep 8, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "Chief Financial Officer Appointment AdaptHealth Corp. (the 'Company') announced today that Harriss Currie, age 64, has been appointed to serve as the Chief Financial Officer of the Company, effective as of September 9, 2026 (the..."
AdaptHealth Corp. filed a Form 8-K on Jul 2, 2026 (Item 1.05) that OQRO classes as: reported a cybersecurity incident.
The company's own opening sentence of that report reads: "AdaptHealth Corp. (the 'Company') is investigating a security incident whereby a threat actor gained unauthorized access to Company systems and exfiltrated certain data therefrom."
AdaptHealth Corp. filed a Form 8-K on Jun 2, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On May 5, 2026, AdaptHealth Corp. (the 'Company') filed a Current Report on Form 8-K (the 'Original Filing') reporting, among other things, the appointment of Daniel McFadden as Chief Operating Officer of the Company, effective a..."
Press coverage listed by Finnhub: "AdaptHealth Corp. to Participate in Upcoming Investor Conference" (Yahoo, Nov 4, 2026).
Press coverage listed by Finnhub: "AdaptHealth's Capitated Contract Margins Improve, RBC Says" (Yahoo, Nov 4, 2026).
Press coverage listed by Finnhub: "AdaptHealth Corp. 2026 Q3 - Results - Earnings Call Presentation" (SeekingAlpha, Nov 4, 2026).
AHCO closed at $7.37 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $5.88 to $7.37, a change of +25.3%.
Who holds it
237 funds reported a stake in AdaptHealth Corp. in their 13F for Q2 2026. The largest by value: OEP CAPITAL ADVISORS, L.P. (11.5% of the value reported), BlackRock, Inc. (11.3% of the value reported), DEERFIELD MANAGEMENT COMPANY, L.P. (8.1% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 19, 2025, AHCO is down 20.9% and the index fund is up 4.1%: 25 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AHCO moves
A usual day
±1.5%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.7%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−38.0%Aug 4, 2026
Largest one-day rise
+16.4%Nov 4, 2026
Deepest fall of the year
−61.0%From the close of Apr 28, 2026 to Aug 10, 2026.
Days of 5% or more
22Out of 252 sessions, in either direction.
Beta 0.2(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).